A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
{{output}}
Purpose: This research examined the cost-effectiveness of adding empagliflozin to standard of care (SoC) compared with SoC alone for treatment of heart failure with reduced ejection fraction (HFrEF) from the perspective of health... ...
